Home › Research › Treatments
Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies
Rautela R, Gupta SM, Gaurav A.. Research Square, 2026-08-06
Topic: Drug trials: efficacy and safety
Plain-language summary
Alzheimer’s disease (AD) represents a progressively growing worldwide public health burden. Despite therapeutic advances, cholinesterase inhibition remains a primary pharmacological target against AD. Excessive depletion of acetylcholine by acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) contributes to cognitive impairment in AD. Current therapeutics largely rely on AChE inhibition and remain constrained by several adverse effects. Hence, these limitations highlight the growing need to identify a new dual cholinesterase inhibitor from natural sources that offers better efficacy with fewer side effects. In recent years, labdane- related diterpenoids have attracted significant attention for their reported anticholinesterase efficacy, in tandem with their anti-inflammatory, antioxidant, and neuroprotective properties. The current workflow leveraged a ligand-based pharmacophore model developed using labdane-related diterpenoids with reported cholinesterase inhibitory activity to perform multi-step virtual screening of natural product databases, aided by molecular docking coupled with molecular dynamics simulation. Four compounds were identified through a multi-step virtual screening procedure, which showed favorable pharmacophore fit scores and stable interaction profiles with key catalytic and peripheral anionic site residues of both enzymes. Molecular dynamics simulations further substantiated the conformational stability of the protein-ligand complexes over a 500 ns trajectory. In experimental validation, Corylin showed anti-AChE activity with IC 50 values of 18.03 ± 7.15 µM, and 6-Hydroxy-2,2-dimethylchroman-4-one exhibited inhibitory activity against BuChE with 102 ± 4.64. Among them, Glabridin showed dual inhibition with IC 50 values of 12.7 ± 6.09 µM for AChE and 156.16 ± 4.64 µM for BuChE. Kinetic studies revealed that Glabridin acts in a non-competitive manner with AChE and mixed-type inhibition in competitive mode with BuChE, with K i values of 27.59 µM and 56.42µM, respectively. The present study identified Glabridin as a promising dual cholinesterase inhibitor and demonstrated the precision of pharmacophore-based virtual screening integrated with experimental evaluation, thereby providing a rational strategy for identifying multifunctional lead compounds for AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rautela, R., Gupta, S. M., & Gaurav, A. (2026). Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies. Research Square. https://doi.org/10.21203/rs.3.rs-10417596/v1
Vancouver
Rautela R, Gupta SM, Gaurav A. Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies. Research Square. 2026. doi:10.21203/rs.3.rs-10417596/v1.
BibTeX
@article{rautela2026-3e3bf661,
author = {Rautela, R. and Gupta, S. M. and Gaurav, A.},
title = {{Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-10417596/v1},
url = {https://doi.org/10.21203/rs.3.rs-10417596/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In recent years, labdane- related diterpenoids have attracted significant attention for their reported anticholinesterase efficacy, in tandem with their anti-inflammatory, antioxidant, and neuroprotective properties.
- Kinetic studies revealed that Glabridin acts in a non-competitive manner with AChE and mixed-type inhibition in competitive mode with BuChE, with K i values of 27.59 µM and 56.42µM, respectively.
- The present study identified Glabridin as a promising dual cholinesterase inhibitor and demonstrated the precision of pharmacophore-based virtual screening integrated with experimental evaluation, thereby providing a rational strategy for identifying multifunctional lead compounds for AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “repurposing”
234 studies in the library carry the topic tag “repurposing”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 234 tagged studies.